Skip to main content

Posts

Dr. Mortimer Mishkin to be Awarded National Medal of Science

From an NIH press release: NIMH's Dr. Mortimer Mishkin to be awarded National Medal of Science 12 November 2010 National Institutes of Health intramural researcher Mortimer Mishkin, Ph.D., will be awarded the National Medal of Science at a White House ceremony later this month. Mishkin is chief of the National Institute of Mental Health’s (NIMH) Section on Cognitive Neuroscience, and acting chief of its Laboratory of Neuropsychology. He is the first NIMH intramural scientist to receive the medal, which the President presents each year for outstanding contributions to science. Mishkin is among 10 recipients this year. "I'm hugely honored. I also feel very happy because it reflects on the support I’ve received from NIH/NIMH all these years," said Mishkin, who has worked at the NIMH Intramural Research Program on the NIH campus in Bethesda, Md. since 1955. In a series of meticulous studies spanning more than five decades, Mishkin and colleagues discovered much about how ...

Alzheimer's Disease: Rethinking Things?

A very readable piece from Gina Kolata of the New York Times: Doubt on Tactic in Alzheimer’s Battle By GINA KOLATA The New York Times Published: August 18, 2010 "The failure of a promising Alzheimer’s drug highlights the gap between diagnosis and treatment." Read the full article

Colin Blakemore: "The House I Grew Up In" (BBC Radio 4)

Audio available from The BBC : Listen From the show's webpage: "Neurobiologist Professor Colin Blakemore was a war baby brought up in devastated Coventry. His two-up two-down home had the first TV in the street on which he lived next door to relatives and a family of ten. As an only child, his parents were able to cash in an insurance policy of £16 which enabled him to go to the local grammar school where he proved himself to be more of an artist and actor than a scientist. Producer: Smita Patel."

Potiga (ezogabine)

From FierceBiotech FDA panel backs new epilepsy drug from GSK, Valeant August 12, 2010 — 7:41am ET By John Carroll "GlaxoSmithKline and Valeant got a solid endorsement for their new epilepsy drug Potiga (ezogabine) from the FDA's panel of experts, putting them on track to a likely approval. The experts unanimously agreed that the drug would benefit epilepsy patients whose meds couldn't stop seizures. And they agreed that careful monitoring would flag patients who experience an inability to urinate while taking the drug." Read the full article

OBIT: Dr. Paul Satz

From UCLA: Obituary: Paul Satz Obituary: Paul Satz, 77, psychiatry professor, founder of UCLA neuropsychology program By Mark Wheeler June 25, 2010 UCLA Paul Satz, a UCLA professor emeritus of psychiatry and biobehavioral sciences and the founder of the neuropsychology program at UCLA's Semel Institute for Neuroscience and Human Behavior and Resnick Neuropsychiatric Hospital, died June 20, in Lihue, Hawaii, after a long battle with cancer. He was 77. One of the founders of the discipline of neuropsychology, Satz was widely recognized for his groundbreaking research on brain–behavior relations. During his tenure at UCLA (1981–2002), he established the UCLA Neuropsychology Program and helped turn it into one of the world's largest and most successful training programs for clinical neuropsychologists. The author of more than 300 publications, Satz's scientific contributions to the understanding of normal and abnormal brain development had — and continue to have — a major imp...

NCDEU

NCDEU is an annual conference that presents advances in treatment and in clinical trials for a number of psychiatric conditions. It is a relatively small conference with a nicely organized agenda of workshopa, presentations, and poster sessions. The website for the conference can be found here , which includes the program.